TP53 and central nervous system cancer: Because the revised WHO classification genetically defines astrocytomas, IDH-mutant as gliomas with IDH mutations and an intact 1p/19q, the overall survival curves were analyzed adding 3 IDH mutant gliomas with wild-type TP53 and an intact 1p/19q.